Back to News
Market Impact: 0.35
Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Teva reported positive topline Phase 2a results for TEV 408 (anti-interleukin-15) in adults with celiac disease, stating the study met its primary endpoint with statistically significant outcomes. The update supports clinical progress for an investigational asset and is likely to be viewed favorably by investors, though full efficacy/safety details were not provided in the excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
TEVA0.45
More News
- Christine Lagarde: IMFC Statement
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test